Galmed Pharmaceuticals (GLMD) Operating Income (2013 - 2024)
Galmed Pharmaceuticals (GLMD) posted quarterly Operating Income of $653000.0 for Q2 2024, up 13.96% year-over-year from $573000.0 in Q3 2023, and up 13.96% quarter-over-quarter from $573000.0 in Q2 2023.
Galmed Pharmaceuticals (GLMD) Operating Income (2013 - 2024) Analysis & Trends
Galmed Pharmaceuticals' Operating Income history runs 11 years deep, the most recent figure standing at $653000.0 for Q2 2024.
- In Q2 2024, Operating Income rose 13.96% year-over-year to $653000.0; the TTM figure through Jun 2024 stood at -$4.3 million (down 385.98% YoY), while the FY2025 annual figure was $1.8 million, down 17.22% from the prior year.
- Operating Income for Q2 2024 stood at $653000.0, up from $573000.0 in the prior quarter.
- The five-year high for Operating Income was $6.5 million in Q1 2020, with the low at -$5.8 million in Q2 2020.
- The 4-year median for Operating Income is $573000.0 (2023), against an average of $431600.0.
- The sharpest annual moves came in 2020 and 2023: Operating Income fell 23.72% in 2020, then jumped 100.35% in 2023.
- Galmed Pharmaceuticals' Operating Income stood at -$5.8 million in 2020, then jumped by 104.92% to $286000.0 in 2022, then jumped by 100.35% to $573000.0 in 2023, then grew by 13.96% to $653000.0 in 2024.
- Business Quant data shows GLMD's Operating Income at $653000.0 in Q2 2024, $573000.0 in Q2 2023, and $286000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 653,000.00 |
| Jun 30, 2023 | 573,000.00 |
| Jun 30, 2022 | 286,000.00 |
| Jun 30, 2020 | -5.82 Mn |
| Mar 31, 2020 | 6.46 Mn |
| Jun 30, 2019 | -4.70 Mn |
| Mar 31, 2019 | 4.04 Mn |
| Mar 31, 2018 | 2.56 Mn |
| Mar 31, 2017 | 3.26 Mn |
| Sep 30, 2016 | 3.81 Mn |
| Jun 30, 2016 | 4.22 Mn |
| Mar 31, 2016 | 4.10 Mn |
| Sep 30, 2015 | 2.50 Mn |
| Jun 30, 2015 | 2.53 Mn |
| Mar 31, 2015 | 2.50 Mn |
| Jun 30, 2014 | 1.76 Mn |
| Mar 31, 2014 | 2.14 Mn |
| Jun 30, 2013 | 948,000.00 |
| Mar 31, 2013 | 603,000.00 |